MDM2 and acute myeloid leukemia: The MDM2 inhibitor milademetan + low-dose cytarabine with or without venetoclax is being studied in patients with relapsed/refractory AML (NCT03634228), and siremadlin (HDM201) will be studied in a two-arm study in combination with azacitidine + ventoclax and allowed to enroll with TP53m-AML (NCT05155709).